Answers are grounded in this paper and cite their sources.
Shows FTO inhibits proliferation and EMT in non-small cell lung cancer, indicating a potential therapeutic target.
A modification in NSCLC cells. FTO attenuates IGF2BP2-mediated mRNA stability of Cyclin E1 and Cyclin D1, supporting the notion that FTO suppresses EMT and proliferation in NSCLC cells via an IGF2BP2-dependent mechanism. Taken together, our findings highlight the critical role of FTO in regulating Cyclin E1 and Cyclin D1, and establish the interaction mechanism between FTO and Cyclin E1/Cyclin D1 in controlling EMT and proliferation in NSCLC cells.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: